Lazard US Convertibles Portfolio Open (CONOX)
11.08
-0.29
(-2.55%)
USD |
Nov 20 2026
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.00% | 15.78M | -- | 51.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -1.656M | 3.16% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Lazard US Convertibles Portfolio invests at least 80% of its assets in convertible securities that are economically tied to the US issued by corporations issued or guaranteed by governments or its instrumentalities; or issued by a supranational organization. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | -- |
| Broad Asset Class | Allocation |
| Broad Category | Fixed Income |
| Global Peer Group | Bond Convertibles US |
| Peer Group | Convertible Securities Funds |
| Global Macro | Bond Other |
| US Macro | Mixed-Assets Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Convertible Securities Funds |
| Fund Owner Firm Name | Lazard |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Fund Flows
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of November 21, 2026.
Asset Allocation
As of September 30, 2026.
| Type | % Net |
|---|---|
| Cash | 0.00% |
| Stock | 0.00% |
| Bond | 77.11% |
| Convertible | 0.00% |
| Preferred | 18.67% |
| Other | 4.22% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Alphabet Inc PFD
|
4.39% | -- | -- |
| Snowflake Inc. SNOWINC 0.0 10/15/2029 FIX USD Corporate 144A | 3.75% | 93.88 | 0.08% |
|
Lazard Government Money Market Portfolio
|
3.06% | -- | -- |
| Live Nation Entertainment, Inc. LNEINC 2.875 01/15/2030 FIX USD Corporate | 2.92% | 111.18 | -1.47% |
| Strategy Inc STRATEAA 0.0 12/01/2029 FIX USD Corporate 144A | 2.70% | 87.73 | -1.01% |
| NextEra Energy Capital Holdings, Inc. NXTENG 3.0 03/01/2027 FIX USD Corporate 144A | 2.50% | 122.74 | -0.41% |
| CoreWeave, Inc. COREWEI 1.75 12/01/2031 FIX USD Corporate 144A | 2.36% | 63.30 | -7.80% |
| BRIDGEBIO PHARMA, INC. BRIDGPH 2.25 02/01/2029 FIX USD Corporate 144A | 2.30% | 107.41 | -1.73% |
| Welltower OP LLC WELLTOO 2.75 05/15/2028 FIX USD Corporate 144A | 2.27% | 252.28 | -1.44% |
| AKAMAI TECHNOLOGIES, INC. AKAM 0.375 09/01/2027 FIX USD Corporate | 2.23% | 101.63 | -1.75% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 0.25% |
| Actual Management Fee | -- |
| Administration Fee | 300.00 None |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2500.00 None |
| Minimum Subsequent Investment | 50.00 None |
TTM Distributions
| Type | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of October 31, 2026.
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Lazard US Convertibles Portfolio invests at least 80% of its assets in convertible securities that are economically tied to the US issued by corporations issued or guaranteed by governments or its instrumentalities; or issued by a supranational organization. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | -- |
| Broad Asset Class | Allocation |
| Broad Category | Fixed Income |
| Global Peer Group | Bond Convertibles US |
| Peer Group | Convertible Securities Funds |
| Global Macro | Bond Other |
| US Macro | Mixed-Assets Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Convertible Securities Funds |
| Fund Owner Firm Name | Lazard |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (11-20-26) | 4.74% |
| 30-Day SEC Yield (10-31-26) | 0.96% |
| 7-Day SEC Yield | -- |
| Number of Holdings | 100 |
| Bond | |
| Yield to Maturity (9-30-26) | -2.88% |
| Effective Duration | 1.26 |
| Average Coupon | 2.11% |
| Calculated Average Quality | 4.152 |
| Effective Maturity | 3.234 |
| Nominal Maturity | 3.234 |
| Number of Bond Holdings | 82 |
As of September 30, 2026
Fund Details
| Key Dates | |
| Inception Date | 12/30/2022 |
| Last Annual Report Date | 12/31/2025 |
| Last Prospectus Date | 5/1/2026 |
| Share Classes | |
| CONIX | Inst |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | No |
| Leveraged Fund | -- |
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:CONOX", "name") |
| Broad Asset Class: =YCI("M:CONOX", "broad_asset_class") |
| Broad Category: =YCI("M:CONOX", "broad_category_group") |
| Prospectus Objective: =YCI("M:CONOX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |